Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 20 and \< 45 years healthy female and male~2. General good health based on history and clinical examination.~3. Written informed consent obtained before any trial procedure.~4. Female and male volunteers practicing contraception before and up to four (4) weeks after the third vaccination.~5. Available to participate in follow-up for the duration of trial.~6. Reachable by phone during the whole trial period.~7. Volunteers should be affiliated to a social security regimen~Exclusion Criteria:~1. Positive pregnancy test~2. Active breast feeding~3. Previous participation in any malaria vaccine trial~4. History of blood transfusion within the last 6 months~5. Symptoms, physical signs or laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers.~6. Any clinically significant laboratory abnormalities on screened blood samples outside the normal range, as defined at the clinical trial site.~7. Enrolment in any other clinical trial during the whole trial period~8. Intake of chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the thirteen weeks preceding the screening visit or during the trial period except topical steroid use including intranasal.~9. Any confirmed or suspected immunosuppressive or immunodeficiency condition during the whole trial period~10. Volunteers unable to be closely followed for social, geographic or psychological reasons.~11. Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the trial.~12. History of anaphylaxis or Known severe hypersensitivity to any of the vaccine components (adjuvant or antigen or excipient)~13. Vaccination or gamma globulin: 4 weeks prior and after each vaccination if a vaccination is necessary during this period, the volunteer will be withdrawn from the study.~14. Positive HIV, HBV (Ag HBS) and HCV tests.~15. History of malaria or travel in malaria endemic areas within the past twenty-six weeks.~16. Positive serology for malaria antigen PfAMA-1~17. Intention to travel to malaria endemic countries during the trial period.~    -

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AMA1-DiCo + Alhydrogel (Type: EXPERIMENTAL): AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
- AMA1-DiCo+ GLA-SE (Type: EXPERIMENTAL): Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26
- AMA1-DiCo + GLA-SE (Type: EXPERIMENTAL): Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26
- Placebo (Type: PLACEBO_COMPARATOR): Group B2 (18) : African volunteer : Placebo~Placebo : isotonic saline solution~Route : Intramuscular Vaccination schedule : Do, W4, W26

Based on this trial design, predict the completion outcome and termination type (if applicable).